These research findings illustrate the value of research into the intricate processes underlying the alteration of synaptic and axonal proteins by pathogenic α-synuclein and highlight the potential these revelations have in formulating new treatments that could target the neurological dysfunctions that are faced by those that are suffering with PD, rather than just offering them motor-based symptomatic-relief. The gene discussed is SNCA; the disease is Parkinson disease.